Full Library
Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas
Resource type
Journal Article
Authors/contributors
- Cullen, Michael (Author)
- Steven, Neil (Author)
- Billingham, Lucinda (Author)
- Gaunt, Claire (Author)
- Hastings, Mark (Author)
- Simmonds, Peter (Author)
- Stuart, Nicholas (Author)
- Rea, Daniel (Author)
- Bower, Mark (Author)
- Fernando, Indrajit (Author)
- Huddart, Robert (Author)
- Gollins, Simon (Author)
- Stanley, Andrew (Author)
Title
Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas
Abstract
In this trial, 1565 patients who were receiving cyclic chemotherapy for solid tumors or lymphoma and who were at risk for temporary, severe neutropenia received either 500 mg of levofloxacin once daily or placebo for seven days. At least one febrile episode occurred in 15.2 percent of the placebo group and 10.8 percent of the levofloxacin group (P=0.01). Hospitalization was required for the treatment of infection in 21.6 percent of the placebo group and 15.7 percent of the levofloxacin group (P=0.004). Antimicrobial resistance was not systematically evaluated.
Publication
New England Journal of Medicine
Date
September 8, 2005
Volume
353
Issue
10
Pages
988-998
Accessed
12/6/20, 10:10 AM
ISSN
0028-4793
Library Catalog
Taylor and Francis+NEJM
Extra
Publisher: Massachusetts Medical Society
_eprint: https://doi.org/10.1056/NEJMoa050078
PMID: 16148284
Citation
Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P., Stuart, N., Rea, D., Bower, M., Fernando, I., Huddart, R., Gollins, S., & Stanley, A. (2005). Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas. New England Journal of Medicine, 353(10), 988–998. https://doi.org/10.1056/NEJMoa050078
HEME-ONC AND CELLULAR THERAPIES
Link to this record